A 66-year-old man with a history of small cell lung cancer presented to the hospital for a third trial of chemotherapy. The patient had been treated by chemotherapy consisting of ifospamide, carboplatin and etoposide for two sessions. An follow-up enhanced chest computed tomography (CT) scan demonstrated a marked decrease of the size of the mass. However, the CT scan (Fig. 1A, B) showed a newly developed intraluminal-filling defect of a thrombus from the mid thoracic aorta to just above the celiac trunk. The aortic thrombus did not accompany an aneurysm, dissection or atherosclerotic change. Two months ago, there was no aortic thrombus seen on a CT scan (Fig. 1C ). As the patient had thrombocytopenia and did not show any complications associated with the aortic thrombosis, the physician decided to proceed with close follow-up and no anticoagulation therapy.
Case 2
A 65-year-old man with a history of non-small cell lung cancer visited the hospital for a follow-up enhanced chest CT. The patient was treated with chemotherapy consisting of carboplatin and taxel for six sessions. A follow-up CT scan ( Fig. 2A, B) showed no significant interval change in the lung as compared with the previous CT scan, but demonstrated a newly developed intraluminal filling defect of a thrombus, about 6 cm in length at the level of the thoracoabdominal de-
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Treated with Chemotherapy scending aorta just above the celiac trunk. Forty-five days prior, a CT scan (Fig. 2C) showed no aortic thrombus, aneurysm, dissection or atherosclerotic change. As the patient had thrombocytopenia and did not show any complications associated with the aortic thrombosis, the physician decided to proceed with close follow-up and no anticoagulation therapy.
Discussion
An acute aortic thrombosis in the absence of atherosclerosis, aortic dissection, or aneurysm is an infrequent clinical entity and has been rarely reported in the literature. Although the incidence of an acute aortic thrombosis is very low, it should be recognized carefully because of its serious complications such as a peripheral and visceral embolism. Machleder et al. (1) reported an incidence of 0.45% of a non-aneurysmal aortic mural thrombus in 10,671 consecutive autopsies, with 17% of these patients having an incidence of A distal embolization.
In the pathogenesis of an aortic thrombosis associated with atherosclerotic disease, atherosclerotic lesions have an important role in the formation of the thrombus as a nidus. However, the pathogenesis of a primary aortic thrombus has not yet been defined. The two cases did not relate to an identifiable atherosclerosis. However, both patients had a history of lung cancer, and both patients were treated by cisplatin-based chemotherapy during multiple sessions.
Vascular events such as deep venous thrombosis, pulmonary embolus, arterial thrombosis and embolus, cerebrovascular accident, unstable angina and myocardial infarction have been reported in patients with malignant disease, and the frequency of such events is increased in cancer patients (2, 3) . However, an acute aortic thrombosis is not common in the cancer patient. When we reviewed cases of a few acute aortic throm- boses associated with malignant disease, aortic occlusion was seen in pancreatic adenocarcinoma, T-cell lymphoma and acute myelomonocytic leukemia. Cases of aortic thrombosis in cancer patients occurred in the absence of atherosclerosis, dissection, an aneurysm or any predisposing factors causing the formation of clots. In the cancer patients, the neoplastic lesions were in immediate proximity to the aorta (4).
In a previous study, a close correlation of the thromboembolic events and the location of the cancer for colorectal, prostate, pancreas, lung, and ovary cancers was reported (5) . In the present cases of lung cancer, the aortic thrombosis developed mainly in the abdominal aorta and was not related to the tumor location. Possible contributing factors such as inappropriate intravascular coagulation and fibrinolysis, tumor production of procoagulants, and the physical characteristics of the tumor cells leading to the interaction with components of the clotting and inflammatory cascades may have a role in the thrombotic condition in cancer patients. Furthermore, a poor physical status, decreased activity and compressive effects of the tumor on the vasculature may also increase the risk of thromboembolic events (6, 7).
Czaykowski et al. (7) reported the incidence of thromboembolic events in patients receiving multi-agent chemotherapy for urothelial cancer. In 271 patients that received multi-agent cisplatin based chemotherapy for transitional cell carcinomas, 35 patients (12.9%) showed vascular events and seven patients showed arterial thromboses. The investigators explained the relationship between the vascular events and systemic chemotherapy, and emphasized the necessity of the use of prophylactic anticoagulation in patients with risk fac- tors for thromboembolic disease. The investigators emphasized the cisplatin-related thromboembolic events; there is some evidence that cisplatin can induce platelet activation and aggregation and alter endothelial cell integrity (7) . In addition, Apiyasawat et al. (8) reported a case related to a cisplatin-induced localized aortic thrombus. These investigators reported on a patient with a localized mobile aortic thrombus that was treated with cisplatin and 5-fluorouracil and the patient presented with embolic events to the right lower extremity. The patient did not have any contributing factors related to the hypercoagulable state. In the present cases, the patients were treated with carboplatin. Carboplatin is an analogue of cisplatin that has been used since the 1990s and has fewer side effects but a decreased anti-cancer drug effect than the use of cisplatin. The use of carboplatin may be related to the formation of an aortic thrombus.
Reported cases of an acute aortic or arterial thrombosis were treated successfully by anticoagulation therapy or by performing a surgical thrombectomy (4, 7, 8) . As both patients of the present cases had thrombocytopenia and did not show any complications associated with the aortic thromboses, the physicians decided to proceed with close follow-up and no anticoagulation therapy.
In conclusion, an acute aortic thrombus may occur during chemotherapy of lung cancer, especially with the use of carboplatin, it should be recognized carefully, and proper therapy must be performed. We have presented two cases of acute aortic thrombi during chemotherapy of lung cancer patients with a review of the literature.
